Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18619344 | SYSTEMS AND METHODS TO DETERMINE A LIKELIHOOD OF IMAGING WORKFLOW DELAYS | March 2024 | January 2026 | Abandon | 22 | 1 | 0 | No | No |
| 18584643 | SYSTEMS AND METHODS FOR DENTAL APPLIANCE AND DENTAL LAB QUALITY ASSESSMENT | February 2024 | February 2026 | Abandon | 24 | 1 | 0 | No | No |
| 18392692 | SYSTEM FOR MANAGING PHARMACOTHERAPY AND METHOD OF OPERATING THE SAME | December 2023 | November 2025 | Abandon | 23 | 1 | 0 | No | No |
| 18522039 | SYSTEM AND METHOD FOR GENERATING A GESTATIONAL DISORDER NOURISHMENT PROGRAM | November 2023 | March 2025 | Allow | 15 | 1 | 0 | Yes | No |
| 18517265 | CONNECTIVITY TOLERANT MEDICAL INFORMATION SYSTEM AND METHOD | November 2023 | November 2025 | Abandon | 24 | 1 | 0 | No | No |
| 18042281 | PERSONAL MEDICAL RECORD SYSTEM AND METHOD RELATED TO NONCONTACT SCREENING TREATMENT FOR LARGE-SCALE INFECTIOUS DISEASE | July 2023 | November 2025 | Abandon | 33 | 1 | 0 | No | No |
| 17828239 | SYSTEMS AND METHODS FOR STRUCTURED REPORT REGENERATION | May 2022 | June 2025 | Allow | 37 | 1 | 0 | Yes | No |
| 17633990 | EVALUATION DEVICE AND METHOD FOR BLOOD HEALTH, AND ASSESSMENT METHOD FOR DAMAGE CONTRIBUTION DEGREE OF PHYSIOLOGICAL INDEX | February 2022 | September 2025 | Abandon | 43 | 2 | 0 | No | No |
| 17631644 | SYSTEMS, MEDIA, AND METHODS FOR MEASURING HEALTH CARE PROVIDER PERFORMANCE AND TO OPTIMIZE PROVISION OF HEALTH CARE SERVICES | January 2022 | January 2025 | Abandon | 35 | 2 | 0 | Yes | No |
| 17628991 | Atrial Fibrillation Prediction Model And Prediction System Thereof | January 2022 | January 2025 | Abandon | 36 | 1 | 0 | No | No |
| 17646578 | DECISION SUPPORT TOOLS FOR REDUCING READMISSIONS OF INDIVIDUALS WITH ACUTE MYOCARDIAL INFARCTION | December 2021 | December 2025 | Allow | 47 | 4 | 0 | Yes | No |
| 17619698 | VIRTUAL REALITY THERAPEUTIC SYSTEMS | December 2021 | December 2024 | Abandon | 36 | 1 | 0 | No | No |
| 17614116 | Electronically Supervised Administration of a Pharmaceutical Composition | November 2021 | June 2025 | Abandon | 42 | 2 | 0 | No | No |
| 17455317 | DEVICE-INSULATED MONITORING OF PATIENT CONDITION | November 2021 | July 2025 | Allow | 44 | 3 | 0 | Yes | No |
| 17522537 | METHODS AND SYSTEMS TO OPTIMIZE THE UTILIZATION OF HEALTH WORKER AND ENHANCE HEALTHCARE COVERAGE FOR POPULATION TO DELIVER CRITICAL/IN-NEED HEALTHCARE SERVICES | November 2021 | July 2025 | Allow | 44 | 4 | 0 | Yes | No |
| 17496268 | System and Method for Secure Data Exchange and Management | October 2021 | January 2025 | Abandon | 39 | 3 | 0 | No | No |
| 17486309 | TELEHEALTH INTERACTION TRACKING SYSTEM AND METHOD | September 2021 | March 2025 | Allow | 42 | 3 | 0 | Yes | No |
| 17466894 | CALCULATING VIRAL TRANSFER RISK AND REDUCING EXPOSURE THROUGH OCCUPANCY OPTIMIZATION | September 2021 | October 2024 | Abandon | 37 | 2 | 0 | Yes | No |
| 17463851 | SYSTEM AND METHOD FOR TRACKING SENSITIVE MEDICATIONS | September 2021 | October 2025 | Abandon | 49 | 4 | 0 | Yes | No |
| 17401294 | System and Method for Automated Dosage Calculation and Patient Treatment Life Cycle for a Transgender Patient | August 2021 | February 2024 | Allow | 31 | 0 | 0 | No | No |
| 17384348 | SURGICAL DATA SYSTEM AND CLASSIFICATION | July 2021 | March 2025 | Allow | 44 | 3 | 0 | Yes | No |
| 17422790 | EXPLORATION TOOL FOR PREDICTING THE IMPACT OF RISK FACTORS ON HEALTH OUTCOMES | July 2021 | November 2024 | Abandon | 40 | 2 | 0 | No | No |
| 17354309 | INTEGRATED PATIENT ACQUISITION FOR VIRTUAL CARE | June 2021 | May 2025 | Allow | 47 | 4 | 0 | Yes | No |
| 17330908 | USING CLINICAL NOTES FOR ICU MANAGEMENT | May 2021 | May 2025 | Abandon | 47 | 4 | 0 | Yes | No |
| 17268485 | Computer Vision Monitoring and Prediction of Ailments | May 2021 | September 2025 | Allow | 55 | 2 | 0 | No | No |
| 17289801 | Grouping Neuropsychotypes of Patients with Chronic Pain for Personalized Medicine | April 2021 | February 2025 | Abandon | 45 | 3 | 0 | No | No |
| 17283487 | COGNITIVE ARTIFICIAL-INTELLIGENCE BASED POPULATION MANAGEMENT | April 2021 | July 2025 | Abandon | 51 | 3 | 0 | No | No |
| 17221442 | SYSTEM AND METHOD FOR GENERATING A THYROID MALADY NOURISHMENT PROGRAM | April 2021 | July 2024 | Allow | 39 | 3 | 0 | Yes | No |
| 17201547 | MEDICAL INFORMATION MANAGEMENT APPARATUS, MEDICAL INFORMATION MANAGEMENT SYSTEM, STORAGE MEDIUM, AND MEDICAL INFORMATION MANAGEMENT METHOD | March 2021 | February 2025 | Abandon | 47 | 3 | 0 | Yes | No |
| 17196976 | HEALTH DATA PROCESSING AND SYSTEM | March 2021 | January 2025 | Allow | 46 | 4 | 0 | Yes | No |
| 17197011 | Medzone. | March 2021 | January 2024 | Abandon | 34 | 1 | 0 | No | No |
| 17266754 | CONTROL METHOD FOR ELECTRONIC DEVICE, AND COMPUTER-READABLE RECORDING MEDIUM FOR STORING PROGRAM FOR PERFORMING SAME | February 2021 | September 2025 | Abandon | 56 | 5 | 0 | No | No |
| 17150240 | METHODS AND SYSTEMS FOR INTEGRATING CLINICAL PATHWAY MANAGEMENT SYSTEMS WITH ELECTRONIC MEDICAL RECORD DATABASES | January 2021 | February 2026 | Abandon | 60 | 4 | 0 | Yes | Yes |
| 17047448 | SYSTEMS AND METHODS FOR PROVIDING PERSONALIZED ORAL CARE FEEDBACK TO A USER | October 2020 | August 2025 | Abandon | 58 | 4 | 0 | No | No |
| 16947388 | PROACTIVE CONTACT TRACING ASSOCIATED WITH SHARED HEALTH EVENTS | July 2020 | January 2025 | Allow | 54 | 3 | 0 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner EVANS, TRISTAN ISAAC.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 0.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner EVANS, TRISTAN ISAAC works in Art Unit 3683 and has examined 25 patent applications in our dataset. With an allowance rate of 44.0%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 45 months.
Examiner EVANS, TRISTAN ISAAC's allowance rate of 44.0% places them in the 9% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by EVANS, TRISTAN ISAAC receive 2.96 office actions before reaching final disposition. This places the examiner in the 86% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.
The median time to disposition (half-life) for applications examined by EVANS, TRISTAN ISAAC is 45 months. This places the examiner in the 13% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +46.1% benefit to allowance rate for applications examined by EVANS, TRISTAN ISAAC. This interview benefit is in the 91% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 21.3% of applications are subsequently allowed. This success rate is in the 25% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 12.5% of cases where such amendments are filed. This entry rate is in the 13% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.
When applicants file petitions regarding this examiner's actions, 160.0% are granted (fully or in part). This grant rate is in the 97% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 40% percentile). This examiner makes examiner's amendments less often than average. You may need to make most claim amendments yourself.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 43% percentile). This examiner issues Quayle actions less often than average. Allowances may come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.